Sarcomatoid hepatocellular carcinoma in a young African female

Abid M Sadiq¹,², Minael G Mjemmas¹, Adnan M Sadiq²,³ and Gilbert Z Nkya²,⁴

Abstract
Sarcomatoid hepatocellular carcinoma is a rare primary malignant liver cancer. The pathogenesis is unclear; however, the risk factors may be similar to that of conventional hepatocellular carcinoma. We present an 18-year-old female who was admitted due to generalized tonic-clonic convulsions. On examination, we palpated a large non-tender mass in the right upper quadrant. An abdominal computed tomography identified it as hepatocellular carcinoma, and spindle-shaped cells were seen on histopathology. She was counseled on her prognosis but opted for local herbal medications rather than chemotherapy, but unfortunately passed away. We present a rare subtype of hepatocellular carcinoma in a young female which is commonly seen in males above the age of 50 years, and despite its grade and stage, overall survival is poor.

Keywords
Sarcomatoid, hepatocellular carcinoma, non-cirrhotic liver, young adult, Tanzania

Date received: 3 May 2021; accepted: 23 September 2021

Introduction
Hepatocellular carcinoma (HCC) is the main type of liver cancer, accounting for up to 75%–85% of cases.¹ Males are mainly affected with a male-to-female ratio exceeding 2.5 for both incidence and mortality.² More than 80% of HCC cases occur in low-income and lower-middle-income countries, particularly in Eastern Asia and sub-Saharan Africa.³

Sarcomatoid hepatocellular carcinoma (SHC) is a rare type accounting for less than 5% of HCC, which consists of epithelial and mesenchymal spindle cells.⁴⁵ SHC is a distinct subtype of HCC identified histologically by spindle-shaped cells with increased mitotic activity.⁴ We present an 18-year-old female with a large liver mass in the absence of cirrhosis and major risk factors, with spindle-shaped cells on histopathology.

Case report
An 18-year-old female was admitted with a complaint of generalized tonic–clonic convulsions 24 h before admission. She reported three episodes of convulsions each lasting within 2 min and preceded by a frontal headache. She was healthy-looking, and not pale with a hemoglobin of 13.9 g/dL. She was not jaundiced, and there were no palpable lymph nodes. Her abdomen was asymmetrically distended with an irregular hard liver 7 cm below the right costal margin, and there was no palpable spleen. She did not present with any bone or joint pain and swelling. She was initially loaded with diazepam and later switched to phenytoin due to poor control of her convulsions. No further convulsions were observed during the rest of her stay at the hospital.

Her blood workup showed normal serum total protein and albumin of 71.3 and 48.4 g/L, respectively. The total bilirubin was 14.6 mmol/L with a direct bilirubin of 5.6 mmol/L, an international normalized ratio of 1.25, and aspartate aminotransferase of 35 U/L. She scored 5 points on the Child–Pugh score⁷ labeling her as Class A. Her alpha-fetoprotein level was 5.6 IU/mL (normal = 0–6 IU/mL). She tested negative for human immunodeficiency virus, hepatitis B, and hepatitis C. Her urine for a pregnancy test was negative.

¹Department of Internal Medicine, Kilimanjaro Christian Medical Centre, Moshi, Tanzania
²Kilimanjaro Christian Medical University College, Moshi, Tanzania
³Department of Radiology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania
⁴Department of Pathology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania

Corresponding Author:
Abid M Sadiq, Department of Internal Medicine, Kilimanjaro Christian Medical Centre, P.O. Box 3010, Moshi, Tanzania.
Email: abid.physician@gmail.com
Brain computed tomography (CT) showed no pathology. An abdominal CT (Figure 1) showed a heterogeneous mass in segments V, VI, VII, and VIII of the liver with chunky central calcifications, infiltration into the gallbladder, and no portal vein thrombosis were seen. A biopsy of the lesion (Figure 2) showed spindle cells, and the diagnosis was SHC. Immunohistochemistry of the biopsy showed cytokeratin negative and vimentin negative stains; however, there was background uptake of myoblast determination protein 1 though no nuclear expression (Figure 3).

In the discussion with the oncology team, due to the unresectable nature of the tumor, she was advised on palliative chemotherapy. The patient and family were counseled on her prognosis but opted for alternative therapy instead, and she was discharged home with phenytoin. Regular telephone follow-up and a physical follow-up visit 3 months later reported no complications. However, she reported using local herbal medicine as means of alternative therapy. Unfortunately, 2 months after the follow-up visit, the relatives reported that she had passed away at home.

**Discussion**

This study describes a young female with an incidental finding of a large distinct subtype of HCC. Similar to the conventional HCCs, the sarcomatoid subtype is predominantly seen in males and older ages between 58 and 62 years. In addition, the liver enzymes, serum bilirubin, and alpha-fetoprotein tend to be within the normal range, similar to this study. The risk factors for the development of SHC are similar to that of conventional HCCs, being hepatitis B, hepatitis C, and liver cirrhosis. The pathogenesis is not well-understood but is possibly caused by anti-cancer therapy accelerating the proliferation of the sarcomatous cells being a secondary transformation of the conventional HCC. Although, in this study, no risk factor was identified similar to other studies demonstrating the incidence without any prior exposure to anti-cancer therapy, as SHC can occur in up to 22.5% without an underlying etiology.

Compared with conventional HCC, patients with SHC tend to have poorly differentiated large tumor size, frequent tumor necrosis, advanced stage, higher grade at presentation, and higher rates of lymph node metastases. The CT imaging typically shows peripheral ring enhancement and no enhancement in the center. The delayed and prolonged peripheral enhancement correlates with extensive interstitial space, allowing slow diffusion of contrast between interstitial and vascular spaces.

SHC must be distinguished from hepatic sarcoma, as the diagnosis is based on a combination of immunohistochemistry, morphology, and no epithelial differentiation. Despite the close morphological similarity between SHC and carcinosarcoma, the spindle cells are positive for keratin while the converse holds in carcinosarcoma. Spindle cell rhabdomyosarcoma has been reported in the liver with the cells being positive for myoblast determination protein. SHC must be differentiated from combined tumors with separate primary foci of HCC and sarcoma, as the absence of mixing of different tumors on
histopathology and immunohistochemistry in the different tumors is diagnostic. This study was unable to demonstrate the positivity of either cytokeratin or vimentin in epithelial or mesenchymal marker of the sarcomatoid lesions. However, there have been cases whereby only a third of the cases demonstrate both cytokeratin and vimentin positivity.

To date, there are no specific treatment options for patients diagnosed with SHC. Surgical resection remains the primary treatment option; however, the long-term overall survival of patients with stage II SHC and above was similar to that of patients with advanced stage. However, chemotherapy and an immune checkpoint inhibitor have been observed to improve overall survival.

In Tanzania, the estimated incidence of HCC is 6.8% for males, with a mortality rate of 5.3%. A retrospective study reported that HCC death occurred twice in males than females at 11.3% and 5.1%, respectively. Children and young adults undergoing cancer treatment have expressed physical and financial concerns regarding care and treatment in Tanzanian hospitals. In this study, the patient and family did not want to be financially burdened hence opted for an alternative treatment method; however, the outcome was fatal.

**Conclusion**

We present a sarcomatoid subtype of HCC based on spindle-shaped cells on histopathology. It is an aggressive tumor associated with a rapid clinical course, large tumor size, and advanced stage at the time of presentation. An early diagnosis, using CT and histological analysis, and treatment through appropriate examination, surgical resection, and chemotherapy may improve patient prognosis.

**Acknowledgements**

The authors thank the patient and family for their co-operation.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethical approval**

Our institution does not require ethical approval for reporting individual cases or case series.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Informed consent**

Written informed consent was obtained from the patient’s mother for their anonymized information to be published in this article.

**ORCID iD**

Abid M Sadiq https://orcid.org/0000-0002-7812-8042

**References**

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; 68: 394–424.
2. Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. *JAMA Oncol* 2017; 3: 1683–1691.
3. Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. *Nat Rev Gastroenterol Hepatol* 2019; 16(10): 589–604.
4. GianniS, MorsyS, GeropoulosG, et al. The Epidemiology, Staging and Outcomes of Sarcomatoid Hepatocellular Carcinoma: a SEER population analysis. *In Vivo* 2021; 35(1): 393–399.
5. Wu L, Tsilimigras DI, Farooq A, et al. Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: a population-based analysis. *Cancer* 2019; 125: 3767–3775.
6. Giunchi F, Vasuri F, Baldin P, et al. Primary liver sarcomatoid carcinoma: report of two cases and review of the literature. *Pathol Res Pract* 2013; 209(4): 249–254.
7. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 2005; 60: 646–649.
8. Liao S-H, Su T-H, Jeng Y-M, et al. Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma. *Hepatology* 2019; 69(1): 209–221.

9. Kojiro M, Sugihara S, Kakizoe S, et al. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. *Cancer Chemother Pharmacol* 1989; 23(Suppl.): S4–S8.

10. Mitra S, Gupta S, Dahiya D, et al. A rare case of primary sarcomatous hepatocellular carcinoma without previous anticancer therapy. *J Clin Exp Hepatol* 2017; 7(4): 378–384.

11. Numbere N, Zhang D and Agostini-Vulaj D. A rare histologic subtype of hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma: report of a case. *Hepatic Oncol* 2017; 8: HEP33.

12. Koo HR, Park M-S, Kim M-J, et al. Radiological and clinical features of sarcomatoid hepatocellular carcinoma in 11 cases. *J Comput Assist Tomogr* 2008; 32(5): 745–749.

13. Torbenson MS. Morphologic subtypes of hepatocellular carcinoma. *Gastroenterol Clin North Am* 2017; 46: 365–391.

14. Akki AS, Harrell DK, Weaver KD, et al. Rare case of spindle cell/sclerosing rhabdomyosarcoma in adult liver. *Pathology* 2019; 51(7): 745–747.

15. Nishi H, Taguchi K-I, Asayama Y, et al. Sarcomatous hepatocellular carcinoma: a special reference to ordinary hepatocellular carcinoma. *J Gastroenterol Hepatol* 2003; 18: 415–423.

16. Zakka K, Jiang R, Alese OB, et al. Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma. *J Hepatocell Carcinoma* 2019; 6: 119–129.

17. Zhu S-G, Li H-B, Yuan Z-N, et al. Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma: a case report. *World J Gastrointest Oncol* 2020; 12: 1209–1215.

18. International Agency for Research in Cancer. United Republic of Tanzania: cancer statistics. Lyon: International Agency for Research in Cancer, 2019, pp. 1–2.

19. Lyimo EP, Rumisha SF, Mremi IR, et al. Cancer mortality patterns in Tanzania: a retrospective hospital-based study, 2006–2015. *JCO Glob Oncol* 2020; 6: 224–232.

20. Kohi TW, von Essen L, Masika GM, et al. Cancer-related concerns and needs among young adults and children on cancer treatment in Tanzania: a qualitative study. *BMC Cancer* 2019; 19: 82.